Close the sidebar
Home
Stock Market News
Market Sentiment
Trending Industries
Blogs
Contact us
Close the sidebar
Novo Nordisk stock slides Monday on second-generation GLP-1 data
Novo Nordisk's stock dropped 8% due to disappointing results from the Phase 3 trial of its new GLP-1 drug, CagriSema.
